| Dr Patrick Emery O'meara, PHARMD | |
|
401 Bicentennial Way, Santa Rosa, CA 95403-2149 | |
| (707) 217-1181 | |
| Not Available |
| Full Name | Dr Patrick Emery O'meara |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 401 Bicentennial Way, Santa Rosa, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043691405 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 70832 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick Emery O'meara, PHARMD 5 Azurite Ct, Petaluma, CA 94952-5288 Ph: (707) 217-1181 | Dr Patrick Emery O'meara, PHARMD 401 Bicentennial Way, Santa Rosa, CA 95403-2149 Ph: (707) 217-1181 |
News Archive
Jersey Shore University Medical Center is pleased to announce that Mark G. Martens, M.D. chairman of Department of Obstetrics and Gynecology, was honored in November by the Southern Medical Association (SMA) with the Robert D. and Alma W. Moreton Original Research Award.
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
› Verified 5 days ago
Mr. Gregory Lee Kappes, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1055 W College Ave, Santa Rosa, CA 95401 Phone: 707-484-7104 | |
Christopher Nhiawa Vang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3093 Marlow Rd, Santa Rosa, CA 95403 Phone: 707-569-8504 | |
Jie Giok Rahardja, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-393-4652 | |
Conor William Bowman, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 818-522-1238 | |
Dr. Justin Colucci, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-393-4119 Fax: 866-296-6825 | |
Dr. Michael Wollman Sanders I, PHARM.D., C.G.P. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 128 Alderbrook Dr, Santa Rosa, CA 95405 Phone: 707-545-0742 Fax: 707-545-0742 | |
Mr. Mark Allen Guttormsen, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1055 W College Ave, Santa Rosa, CA 95401 Phone: 707-575-1313 Fax: 707-575-0104 |